My research to develop a cure for Malaria began over 8 years ago when my wife, Bonita, and I conducted medical missions in Port-du-Prince, Haiti. At a Christian orphanage directed by Roberta Audate, we observed malaria for the first time. Having seen the advantages of using low dose chemotherapy drugs in treating cancer, where the immune system remains intact and active against the cancer, I decided to help Roberta with the children in her care by giving them low dose PeroxyBioFlavonoids. We used an extended time of 16 days in the hope of immunizing the patients against the malaria by transitioning through the IgM/IgG maturation and stimulating whatever innate immunity that may also play a role. With Haitian governmental approval for a time, we were able to follow the effects of my treatment over the years in over 500 people. Though not using the normal protocol for a scientific study, this group included a close knit community of 15 churches. Furthermore, Children were selected and followed from a daily feeding program conducted by Roberta with over 165 children, including Roberta’s 20+ children who lived at her house. We saw no failures. Dr. Jerry Thornthwaite CuringAndPreventing.com

1. MALARIA
ChristopherWright
Micah England
WidlordThomas

4. Haiti
Nigeria

5. Malaria Treatment
 What is Malaria?
 History of MalariaTreatments
 What PeroxyBioFlavonoid™?
 How does it work?
 Our Research
 Sources of Artemisinin

6. What is Malaria?
 Parasitic disease of red blood cells
 Mosquito carrier
 225 Million cases in 2009
 1.28 Million deaths in 2010
 Haiti
 30,000 reportedCDC
 200,000 unreported CDC
 Haiti has the most dangerous type
of malaria...Plasmodium falciparum.

7. History of Malaria Treatments
 200 BC China SweetWormwood
 1997 Chinese isolated the Artemisinin
 They did not reveal it until recent years
 Current Drugs – chloroquine, atovaquone-proguanil (Malarone®)
artemether-lumefantrine (Coartem®), mefloquine (Lariam®), quinine, quinidine
doxycycline (used in combination with quinine)
clindamycin (used in combination with quinine)
Artemether-lumefantrine (Coartem®) FDA
not approved for patients with severe or complicated P. falciparum malaria.
not approved for the prevention of malaria
Artemisinin is safe with minimum side effects as stated by FDA
However, Artemisinin alone is not enough

8. PeroxyBioFlavonoid™Peroxide Bridge
How it Kills the Parasites
Malaria parasite breaks down Hemaglobulin
and releases iron. The peroxide causes a free
radical chain of events initiated by the Fe and
also within the mitochondria that destroy the
parasite. The BioFlavonoid inhibits three
enzymes in the intestines that can breakdown
Artemisinin and provides antioxidant activity to
immune cells
Protection from Malaria Recurrence (Theory)
■ Rapid release of malaria proteins as antigen source
■ So-called “Super Antigens” with apoptotic parasites and
adjuvant effects
■ Natural KillerCell Function
■ Most Effective Antibodies, IgG1 and IgG3
■ Minimize Pro-inflammatory Cytokines (IFN,TNF, IL1) to avoid
severe pathology
■ Boost the Immunity with supplements taken during the trials

9. PeroxyBioFlavonoid™ Capsules
 Simple, Oral Dose (one 50mg tablet for children with two
tablets for each of 16 days)
 Fast symptom relief (2-3 days)
 Dramatic Clearance (95% parasite clearance within 2-3
Days)
 No Recurrences (Haiti none in over 600 cases; or 92 cases
in Nigeria to date)
 Inexpensive
 Proven in clinicals in Haiti and Nigeria
 Patented process to prevent capsule dissolving
in the stomach

10. PeroxyBioFlavonoid™ Capsules

11. Haiti Minister of Health, Dr. Charles, Harry
Hames of Helping Hands International, Roberta
and Malaria Treatment approval
Roberta
Minister of
Health
Dr. Charles
Bonita
Mr..Hames

12. Results of PeroxyRiboFlavonoid
Treatment

13. Roberta with her seven Children who all had Malaria as Babies.The oldest was nine years ago.

16. NigerianClinical and Economic Approval
140 mi

17. NigerianClinical and Economic Approval
PROTOCOL FOR THE STUDY OF PEROXYBIOFLAVONOID IN THE
TREATMENT OF MALARIA IN SOUTH-WESTERN NIGERIA
The goals of this Human Subjects study are to determine the overall
curative rate of Plasmodium falciparum in 70 patients and determine
the mechanism of action in serum samples obtained from them.
The Principal Investigators:
Dr. Olufemi Akanni, Department of Biomedical Sciences, College of Health Sciences,
(Mercyland Campus) Dada Estate, Osogbo. Osun - State. Nigeria.
Dr. Jerry T. Thornthwaite, Director, Cancer Research Institute of West Tennessee,
114 East Main Street, Henderson, USA.
Study Clinician & Co-Investigator:
Dr. Akeem Ayankunle, Head of Malaria Research Laboratory,
Department of Pharmacology & Therapeutics, Ladoke Akintola University of Technology
(Isale-Osun Campus), Osogbo, Osun State. Mobile: 08061670022.
The final study actually included 112 Patients

19. Progress Reports from Nigeria 4-5-15
Dear Prof. Compliment of the Easter season to you and family. You are
welcome back from Haiti.
I am glad to inform you that we started the study last month and also
to tell you that the antimalarial formulation is performing amazingly
well on the malaria patients so far recruited. The patients appear to
recover fast from pyrexia and even get well fast. As far as the study
is concerned, the recruitment process is slow owing to some reasons
from our strict exclusion criteria:
- Most patients are already on one form of antimalarial drug/treatment
before coming
to the health facilities we are using hence excluded (most
drugs are not efficient or
malaria parasites are resistant to them).
- Some patients complain about the long duration of treatment hence
not ready to give
consent.
- Some patients have low parasitemia load hence not recruitable since
we want those
with severe form of malaria for the study.
- Also, the raining season when cases of malaria infection is very
high is just starting
(ie moving from dry season to raining) in the tropical countries.
- Some health facilities are on industrial action due to unpaid salaries.
However, we are trying to connect another big health facility with our
approval to commence the study to increase chances of fast recruitment
this week after Easter break.
So far we have recruited only 7 patients which we hope to improve
tremendously from next week. This slow pace has caused delay or
prolonged duration of the study than proposed.
I belief we are getting good results and much more when you carry out
immunological assays hopefully. I’m sure this is going to be a major
breakthrough in antimalarial treatment to save millions of patients in
Africa and other malaria endemic countries.
Thank you, Olufemi

20. Progress Reports from Nigeria 4-24-15
Dear Prof. No doubt, the antimalarial treatment is working and I want to belief that the serum
immunologic testings will support our claim and provide reason for no further occurrence of malaria
infection in patients. Please keep working on possibility of reducing the treatment duration of 16 days
possibly before it hits the African huge market soon.
We hope recruitment will keep improving as we start moving into raining season.
Thanks.
OLUFEMI.
Progress Reports from Nigeria 5-1-15 & 5-9-15 & 5-24-15
5-1-15
Dear Prof.
I'm glad to inform you that as at today we have recruited 35 patients with 3 lost to follow-up. The patients are doing well.
Warm regards. Olufemi.
5-9-15
Till date we have recruited 76 patients into the study in Nigeria with
4 individuals lost to follow up. Also, we recorded 3 cases of relapse
after day 30 when the patients reported for blood collection with high
fever and tested positive for malaria parasites. We are feeling the
relapse could be due to possible under dose of the formulation which
could also be due to the infants not taking the complete formulation
in the capsule.
I am also planning packaging and courier dispatch of the first batch
of sera obtained so far to your laboratory.
Kindly respond to the relapse cases and any update on the formulation.
Our plan is to continue recruitment to about 90 -100 to cater for
those that could be lost to follow up till day 60.
Our fund/cash is running low kindly start the process of crediting us.
Thank you. Olufemi.
5-24-15
Please may I know what the inventory list should contain?
Alright. I'll work on sending the Sera available so far.
Further
updates to follow soon.
Olufemi

21. 5-13-15
STUDY PROGRESS REPORTS
First one on Easter Sunday with an Easter salutation from my Nigerian Christian
Medical Scientists:
Dear Prof.The antimalarial study is progressing. I'm happy to inform you that the
formulation is working fantastically well on Nigerian patients. No disappointment
so far. Despite the adverse conditions highlighted in the last progress report, we
have recruited 15 patients with our strict inclusion /exclusion criteria. Blood had
been drawn to day 30 in the initial patients awaiting day 60 & final collection.
10 days later:
Dear Prof. No doubt, the antimalarial treatment is working and I want to belief
that the serum immunologic testings will support our claim and provide reason for
no further occurrence of malaria infection in patients. Please keep working on
possibility of reducing the treatment duration of 16 days possibly before it hits the
African huge market soon.
We hope recruitment will keep improving as we start moving into raining season.
Thanks.
OLUFEMI.

24. TABLE 1
Malaria Parasite Free Children
Drs. Akanni/Thornthwaite MALARIA PARASITEMIA LOAD (MPL)
LAB NO. Age Sex Day 0 Day 1 Day 2 Day 3 Day 7 Day 14 Day 30 Day 60 Result
PF/001 13 f 16484 12320 1240 0 0 0 0 0 Cured
PF/005 7 f 12760 6240 440 0 0 0 0 0 Cured
PF/007 9 f 2040 80 0 0 0 0 0 0 Cured
PF/008 10 f 12160 1800 120 0 0 0 0 0 Cured
PF/009 13 f 2480 0 0 0 0 0 0 0 Cured
PF/010 3 f 3560 880 0 0 0 0 0 0 Cured
PF/019 13 f 89040 20480 5640 1160 0 0 0 0 Cured
PF/020 3 f 47760 0 Cured
PF/022 6 f 13200 3640 960 0 0 0 0 0 Cured
PF/023 11 f 15280 4480 880 0 0 0 0 0 Cured
PF/026 11 f 9760 1120 280 0 0 0 0 0 Cured
PF/027 4 f 10960 2240 160 0 0 0 0 0 Cured
PF/029 11 f 2040 160 0 0 0 0 0 0 Cured
PF/036 5 f 4200 360 0 0 0 0 0 0 Cured
PF/037 6 f 3640 200 0 0 0 0 0 0 Cured
PF/038 6 f 3640 840 0 0 0 0 0 0 Cured
PF/041 7 f 3680 1960 120 0 0 0 0 0 Cured
PF/042 11 f 2920 160 0 0 0 0 0 0 Cured
PF/051 7 f 2420 80 0 0 0 0 0 0 Cured
PF/052 4 f 2800 160 0 0 0 0 0 0 Cured
PF/053 4 f 2040 0 0 0 0 0 0 0 Cured
PF/057 12 f 21760 2760 80 0 0 0 0 0 Cured
PF/058 10 f 5120 120 0 0 0 0 0 0 Cured
PF/060 3 f 62840 4840 1360 0 0 0 Cured
PF/064 13 f 4360 320 0 0 0 0 0 0 Cured
PF/072 3 f 2760 80 0 0 0 0 0 0 Cured
PF/075 5 f 2240 480 0 0 0 0 0 Cured
PF/078 f 74400 14680 360 0 0 0 0 Cured
PF/O82 14 f 2360 320 0 0 0 0 0 0 Cured
PF/083 15 f 3240 560 0 0 0 0 0 0 Cured
PF/084 6 f 77640 15520 2120 0 0 0 0 0 Cured
PF/087 15 f 27600 8560 1160 0 0 0 0 0 Cured
PF/088 4 f 3320 280 0 0 0 0 0 0 Cured
PF/089 8 f 84360 25280 1240 0 0 0 0 0 Cured
PF/094 10 f 98240 72680 45160 22280 0 0 0 Cured
PF/098 7 f 18320 5240 2240 160 0 0 0 Cured
PF/100 12 f 9480 2440 160 0 0 0 0 0 Cured
Pf005 9 f 15200 5480 1680 0 0 0 0 0 Cured
Pf009 12 f 2840 120 0 0 0 0 0 0 Cured
Pf012 13 f 4480 1680 560 0 0 0 0 0 Cured
Pf015 15 f 4360 760 0 0 0 0 0 0 Cured
Pf016 12 f 32640 10840 4880 1840 0 0 0 0 Cured
Pf017 12 f 46480 15480 2360 0 0 0 0 0 Cured
Pf019 11 f 3360 480 0 0 0 0 0 0 Cured
Pf021 7 f 22480 4240 0 0 0 0 0 0 Cured
Pf029 11 f 5280 2120 0 0 0 0 0 0 Cured
PF/002 6 m 8800 3440 520 0 0 0 0 0 Cured
PF/003 8 m 31868 6720 0 0 0 0 0 0 Cured
PF/004 4 m 5120 760 0 0 0 0 0 0 Cured
PF/006 4 m 3480 160 0 0 0 0 0 0 Cured
PF/012 7 m 7120 2160 180 0 0 0 0 0 Cured
PF/015 2.5 m 24084 4800 1640 0 0 0 0 0 Cured
PF/017 5 m 2400 440 0 0 0 0 0 Cured
PF/021 7 m 18560 6720 1680 240 0 0 0 0 Cured
PF/024 9.5 m 2120 240 0 0 0 0 0 0 Cured
PF/025 8 m 69040 38240 4360 1280 0 0 0 0 Cured
PF/028 7 m 3480 0 Cured
PF/031 15 m 2160 0 0 0 0 0 0 0 Cured
PF/033 4 m 10320 2880 0 0 0 0 0 0 Cured
PF/034 8 m 52480 12240 4880 200 0 0 0 Cured
PF/035 8 m 22720 3360 160 0 0 0 0 0 Cured
PF/039 14 m 2240 120 0 0 0 0 0 Cured
PF/040 7 m 48360 2240 200 0 0 0 0 0 Cured
PF/046 3 m 14720 2880 0 0 0 0 0 0 Cured
PF/047 5 m 2440 160 0 0 0 0 0 0 Cured
PF/048 11 m 6480 1160 280 714 0 0 0 0 Cured
PF/049 7 m 2720 200 0 0 0 0 0 0 Cured
PF/050 6 m 12440 3440 80 0 0 0 0 0 Cured
PF/O55 9 m 3040 160 0 0 0 0 0 0 Cured
PF/056 10 m 12480 2240 160 0 0 0 0 Cured
PF/059 4 m 15480 7440 2480 0 0 0 0 0 Cured
PF/063 4 m 2880 100 0 0 0 0 0 0 Cured
PF/066 6 m 4840 160 0 0 0 0 0 0 Cured
PF/067 12 m 29200 5440 880 160 0 0 0 0 Cured
PF/069 10 m 4680 200 0 0 0 0 0 Cured
PF/074 11 m 3880 440 0 0 0 0 0 0 Cured
PF/076 10 m 2480 160 0 0 0 0 0 0 Cured
PF/077 15 m 8320 480 0 0 0 0 0 0 Cured
PF/079 15 m 48880 4240 1760 0 0 0 0 0 Cured
PF/080 2 m 62440 16840 2920 160 0 0 0 0 Cured
PF/081 3 m 3640 280 0 0 0 0 0 0 Cured
PF/085 15 m 4360 160 0 0 0 0 0 0 Cured
PF/086 11 m 12480 2240 200 0 0 0 0 0 Cured
PF/090 4 m 48440 13560 2880 0 0 0 0 0 Cured
PF/091 9 m 2960 240 80 0 0 0 0 0 Cured
PF/092 4 m 12880 4880 2000 1160 280 0 0 0 Cured
PF/096 7 m 18480 3040 120 0 0 0 0 0 Cured
PF/099 5 m 99160 66280 6480 1360 280 0 0 0 Cured
Pf001 14 m 3480 440 0 0 0 0 0 0 Cured
Pf002 9 m 32640 22120 3240 280 0 0 0 0 Cured
Pf003 5.5 m 72360 56200 24680 10360 0 0 0 0 Cured
Pf007 13 m 10480 2360 160 0 0 0 0 0 Cured
Pf008 9 m 3560 560 0 0 0 0 0 0 Cured
Pf010 5 m 100040 64160 21960 5120 0 0 0 0 Cured
Pf011 7 m 18800 8640 2360 160 0 0 0 0 Cured
Pf014 6.5 m 16400 5480 2640 560 0 0 0 0 Cured
Pf020 11 m 12880 2840 0 0 0 0 0 0 Cured
Pf022 6 m 2840 160 0 0 0 0 0 0 Cured
Pf023 8 m 100000 15240 8480 2640 0 0 0 0 Cured
Pf024 9 m 2160 240 0 0 0 0 0 0 Cured
Pf030 8 m 14840 7840 4560 520 160 0 0 0 Cured
n=101 8.4 MEAN 20224 6683 1820 526 7 0 0 0
3.6 SD 26339 13683 5696 2520 43 0 0 0

25. Table 2
Children with Recurrent Malaria
LAB NO Age Sex Day 0 Day 1 Day 2 Day 3 Day 7 Day 14 Day 30 Result
PF/011 5 f 55120 4240 0 2880 2400 Failed
PF/065 7 f 50920 10480 1240 480 0 0 28960 Failed
Pf018 8 f 16440 4560 520 0 0 0 8640 Failed
Pf025 12 f 2040 160 0 0 0 0 22160 Failed
PF/018 5 m 69920 2160 8040 Failed
PF/030 7 m 17040 3480 560 0 0 0 32160 Failed
PF/032 12 m 2760 0 0 4840 Failed
PF/043† 10 m 15560 3840 0 0 0 0 4360 Failed
PF/044† 7 m 12560 1480 0 0 6680 Failed
PF/045† 9 m 4360 720 0 0 0 3240 Failed
Pf006 9 m 4640 520 0 0 0 0 4680 Failed
n=11 8.3 22851 3276 387 60 0 504 11469
2.4 24060 3200 495 170 0 1076 10870
†PF/43-45 all males from the same family

26. Table 3
Statistical Data from the Children Treated with the MALSUP™
Average Malaria Parasite Load MPL) at Day 0 Cured: 20,224 ± 26339 SD Recurrent: 22,851 ± 24,060
Average Age of the Patients: Cured: 8.4 ± 3.6 Recurrent: 8.3 ± 2.4
Percentage of Males – Cured: 55.4%
Cure Rate – 90.2%
The True Population Proportion Cure Rate is between 0.847 and 0.957 at a 95% confidence
interval for 121 children total with 101 being cured

29. Summary of Results to Date
112 patients
90.2% had no Parasites by the standard blood test
at
30-60 Days
Failures
All had Parasite content go to Zero
All were positive by Day 3o
Three of the failures were from one family
Clinical Standard of Practice Suggestion –
Repeat, Using adult dosage, no serum draws

30. NutraNanoSphere™ Malaria Formulation
● Simple, Oral Dose
● Drops are stable and completely water soluble
● Bioavailability for 8 nm NutraNanoSpheres™ > 90%
● Does not breakdown in the Stomach and Intestines
● Fast symptom relief – n=5
● Dramatic Clearance –
● No Recurrences –
● Inexpensive
● Can be used in capsules

31. NutraNano Sphere™ Malaria Formulation
● Fast symptom relief –
● Dramatic Clearance –
● No Recurrences – Projected
● Inexpensive -
● Can be used in capsules